Use and Limitations of Blood Platelets as Models for Monoaminergic Neurons

Pletscher, A.; Saner, A.; Laubscher, Andreas; Gräf, Martin

doi:10.1016/b978-1-4832-8363-0.50117-8

Cited by 11 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The situation at present is reminiscent of the current controversy about the role of platelet monoamine oxidase (MAO) in schizophrenia (for references see Pletscher, 1978). Also it is possible that only certain patient groups are likely to be amenable to this biochemical index of the efficacy of CPZ therapy.…”

mentioning

confidence: 97%

Platelet aggregation and chlorpromazine therapy.

Boullin¹,

Know²,

Peters³

et al. 1978

Brit J Clinical Pharma

View full text Add to dashboard Cite

mentioning

confidence: 97%

Platelet aggregation and chlorpromazine therapy.

Boullin¹,

Know²,

Peters³

et al. 1978

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…synthesis and turnover of 5-HT, marked differences exist between these two cell types. Platelets have been considered, therefore, as furnishing limited models for the 5-HT neurones of the brain (Sneddon, 1973;Gordon & Olverman, 1978;Pletscher, 1978).…”

Section: Introductionmentioning

confidence: 99%

Shape Change of Blood Platelets—a Model for Cerebral 5‐hydroxytryptamine Receptors?

Gräf

Pletscher

1979

British J Pharmacology

Self Cite

View full text Add to dashboard Cite

In blood platelets of rabbits isolated by a stractan gradient and incubated in a protein‐poor medium, tryptamine, 5‐hydroxytryptamine (5‐HT) and derivatives, quipazine and mescaline caused a shape change. This shape change was inhibited by low concentrations of methysergide. The most potent antagonists of the 5‐HT‐induced shape change included ergoline derivatives and neuroleptic drugs, which showed high stereoselectivity. (‐f)‐Lysergic acid diethylamide ((+)‐LSD), psilocine and some N',N′‐dimethylated tryptamines acted as mixed agonist‐antagonists. The compounds found to be agonists or mixed agonist‐antagonists on platelets have previously been shown to act also as 5‐HT agonists in the central nervous system (CNS). With regard to 5‐HT antagonists, the 5‐HT receptors of platelets reacted differently from those described earlier in brain areas with dense 5‐hydroxytryptaminergic innervation, but showed similarities to 5‐HT receptors investigated previously in spinal cord, cerebral cortex and possibly reticular formation. It is concluded that platelets may be considered with caution as models for some, but not for all, 5‐HT receptors in the CNS.

show abstract

“…For example, receptors and transport pathways involved in serotonin function are also present in platelets; the latter take up serotonin from the blood and store it in dense granules [1,2]. Whereas, the brain serotonin is involved in memory and learning, anxiety and sleep, its release from platelets at sites of vessel injury induces vasoconstriction, and promotes wound repair.…”

Section: To the Editormentioning

confidence: 99%

Is there a redundancy of β3 and other platelet receptors in the brain and central nervous system?

Nurden

2012

Platelets

View full text Add to dashboard Cite

Use and Limitations of Blood Platelets as Models for Monoaminergic Neurons

Cited by 11 publications

References 0 publications

Platelet aggregation and chlorpromazine therapy.

Platelet aggregation and chlorpromazine therapy.

Shape Change of Blood Platelets—a Model for Cerebral 5‐hydroxytryptamine Receptors?

Is there a redundancy of β3 and other platelet receptors in the brain and central nervous system?

Contact Info

Product

Resources

About